Current Environment: Production

Recall Alert

There is an antibacterial antibiotic recall. Read more →
X

CLAIM YOUR MATCH

Your gift, now MATCHED, will help save lives today — and for generations to come.

DONATE NOW

Education

Undergraduate School

College of the Holy Cross

Worcester, MA

Medical School

University of Massachusetts School of Medicine

Worcester, MA

Residency

Floating Hospital for Children at Tufts Medical Center

Boston, MA

Education

Undergraduate School

University of Pennsylvania

Philadelphia, PA

Medical School

Yale University School of Medicine

New Haven, CT

Internship

Massachusetts General Hospital

Boston, MA

Residency

Massachusetts General Hospital

Boston, MA

Education

Graduate School

MMSc

Harvard Medical School

Boston, MA

Medical School

Brown University

2003, Providence, RI

Internship

Pediatrics

Boston Children's Hospital/Boston Medical Center

2004, Boston, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

2006, Boston, MA

Fellowship

Pediatric Hematology-Oncology

Boston Children's Hospital/ Dana-Farber Cancer Institute

2010, Boston, MA

Publications

  1. Treatment Landscape in Pediatric Immune Thrombocytopenia: Addressing Unmet Needs. Pediatr Blood Cancer. 2025 Jul; 72(7):e31758. View Abstract

  2. Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicenter Cohort Study. Blood Adv. 2025 04 09. View Abstract

  3. Working toward international consensus defining pediatric "refractory ITP". Blood Adv. 2025 Mar 11; 9(5):1244-1245. View Abstract

  4. Real-world insights from a cohort of approximately 2000 individuals who were analysed using a freely available next-generation sequencing anaemia screening programme. Br J Haematol. 2025 Mar 09. View Abstract

  5. Correlation of Genetic Mutation With Outcomes in Children With Hereditary Spherocytosis Undergoing Partial Splenectomy: A Multicentre Study. J Pediatr Surg. 2025 Apr; 60(4):162229. View Abstract

  6. T cell and autoantibody profiling for primary immune regulatory disorders. medRxiv. 2025 Jan 27. View Abstract

  7. Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review. Eur J Haematol. 2025 Mar; 114(3):458-468. View Abstract

  8. Genetic variants in canonical Wnt signaling pathway associated with pediatric immune thrombocytopenia. Blood Adv. 2024 11 12; 8(21):5529-5538. View Abstract

  9. What is in a name: defining pediatric refractory ITP. Blood Adv. 2024 10 08; 8(19):5112-5117. View Abstract

  10. Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT). Br J Haematol. 2024 Oct; 205(4):1489-1496. View Abstract

  11. The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia. Blood Adv. 2024 07 09; 8(13):3578-3582. View Abstract

  12. Comorbidities and complications in adult and paediatric patients with pyruvate kinase deficiency: Analysis from the Peak Registry. Br J Haematol. 2024 Aug; 205(2):613-623. View Abstract

  13. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency. Blood Adv. 2024 05 28; 8(10):2433-2441. View Abstract

  14. Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency. Am J Hematol. 2024 07; 99(7):1415-1419. View Abstract

  15. Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment. Haematologica. 2024 03 01; 109(3):963-967. View Abstract

  16. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines. Lancet Haematol. 2024 Mar; 11(3):e228-e239. View Abstract

  17. Pyruvate kinase activators for treatment of pyruvate kinase deficiency. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):97-106. View Abstract

  18. Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial. J Patient Rep Outcomes. 2023 11 09; 7(1):112. View Abstract

  19. HLA antibodies in fetal and neonatal alloimmune thrombocytopenia. Transfusion. 2023 06; 63(6):1141-1149. View Abstract

  20. The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design. BMJ Open. 2023 03 23; 13(3):e063605. View Abstract

  21. Updates and advances in pyruvate kinase deficiency. Trends Mol Med. 2023 05; 29(5):406-418. View Abstract

  22. Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency. Am J Hematol. 2023 03; 98(3):E57-E60. View Abstract

  23. Pediatric refractory immune thrombocytopenia: A systematic review. Pediatr Blood Cancer. 2023 03; 70(3):e30173. View Abstract

  24. Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia. Blood. 2022 12 29; 140(26):2849-2852. View Abstract

  25. Utilization of an ITP quality improvement pathway improves adherence to management guidelines. Pediatr Blood Cancer. 2023 03; 70(3):e30074. View Abstract

  26. An update on pediatric ITP: differentiating primary ITP, IPD, and PID. Blood. 2022 08 11; 140(6):542-555. View Abstract

  27. SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia. Pediatr Blood Cancer. 2022 07; 69(7):e29760. View Abstract

  28. Diagnosis, monitoring, and management of pyruvate kinase deficiency in children. Pediatr Blood Cancer. 2022 08; 69(8):e29696. View Abstract

  29. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. N Engl J Med. 2022 04 14; 386(15):1432-1442. View Abstract

  30. Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. Blood Adv. 2022 03 22; 6(6):1844-1853. View Abstract

  31. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. Pediatr Blood Cancer. 2022 03; 69(3):e29447. View Abstract

  32. Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant. Pediatr Blood Cancer. 2022 01; 69(1):e29410. View Abstract

  33. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open. 2021 08 27; 11(8):e044885. View Abstract

  34. Response to rituximab in children and adults with immune thrombocytopenia (ITP). Res Pract Thromb Haemost. 2021 Aug; 5(6):e12587. View Abstract

  35. Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2021 08; 19(8):2082-2088. View Abstract

  36. The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. J Thromb Haemost. 2021 08; 19(8):2094-2095. View Abstract

  37. Pyruvate kinase deficiency in children. Pediatr Blood Cancer. 2021 09; 68(9):e29148. View Abstract

  38. Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. J Thromb Haemost. 2021 09; 19(9):2348-2354. View Abstract

  39. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2021 06; 19(6):1585-1588. View Abstract

  40. Preoperative hematocrit and platelet count are associated with blood loss during spinal fusion for children with neuromuscular scoliosis. J Perioper Pract. 2022 04; 32(4):74-82. View Abstract

  41. Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. Pediatr Blood Cancer. 2021 06; 68(6):e29023. View Abstract

  42. Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. Eur J Haematol. 2021 Jun; 106(6):783-787. View Abstract

  43. Comorbidities and complications in adults with pyruvate kinase deficiency. Eur J Haematol. 2021 Apr; 106(4):484-492. View Abstract

  44. International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. J Thromb Haemost. 2021 01; 19(1):287-296. View Abstract

  45. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. Res Pract Thromb Haemost. 2021 Jan; 5(1):69-80. View Abstract

  46. Management of pyruvate kinase deficiency in children and adults. Blood. 2020 09 10; 136(11):1241-1249. View Abstract

  47. The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica. 2020 09 01; 105(9):2229-2239. View Abstract

  48. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol. 2020 11; 146(5):1194-1200.e1. View Abstract

  49. Pyruvate kinase deficiency in a newborn with extramedullary hematopoiesis in the skin. Blood. 2020 08 06; 136(6):770. View Abstract

  50. Characterization of the severe phenotype of pyruvate kinase deficiency. Am J Hematol. 2020 Oct; 95(10):E281-E285. View Abstract

  51. Fatigue in children and adolescents with immune thrombocytopenia. Br J Haematol. 2020 10; 191(1):98-106. View Abstract

  52. COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation. Pediatr Blood Cancer. 2020 09; 67(9):e28382. View Abstract

  53. The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. Br J Haematol. 2021 03; 192(6):1092-1096. View Abstract

  54. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020; 11:2040620720912992. View Abstract

  55. The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica. 2020 Mar 12. View Abstract

  56. Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. Am J Hematol. 2020 05; 95(5):472-482. View Abstract

  57. Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease-specific assessments. Eur J Haematol. 2020 May; 104(5):427-434. View Abstract

  58. Genetic variants in toll-like receptor 4 are associated with lack of steroid-responsiveness in pediatric ITP patients. Am J Hematol. 2020 04; 95(4):395-400. View Abstract

  59. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 12 10; 3(23):3829-3866. View Abstract

  60. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. N Engl J Med. 2019 09 05; 381(10):933-944. View Abstract

  61. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol. 2019 07; 94(7):741-750. View Abstract

  62. Pediatric Hematology. Hematol Oncol Clin North Am. 2019 06; 33(3):xiii-xiv. View Abstract

  63. Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review. Am J Hematol. 2019 04; 94(4):461-466. View Abstract

  64. How we manage patients with pyruvate kinase deficiency. Br J Haematol. 2019 03; 184(5):721-734. View Abstract

  65. The burden of disease in pyruvate kinase deficiency: Patients' perception of the impact on health-related quality of life. Eur J Haematol. 2018 Dec; 101(6):758-765. View Abstract

  66. Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019 02; 104(2):e51-e53. View Abstract

  67. Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2018 Jul; 46(1):81-83. View Abstract

  68. Red Blood Cell Enzyme Disorders. Pediatr Clin North Am. 2018 06; 65(3):579-595. View Abstract

  69. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. Am J Hematol. 2018 07; 93(7):882-888. View Abstract

  70. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood. 2018 05 17; 131(20):2183-2192. View Abstract

  71. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018 Feb; 45(2):306-314. View Abstract

  72. Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity. Thromb Haemost. 2018 01; 118(1):143-151. View Abstract

  73. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer. 2018 Jan; 65(1). View Abstract

  74. Second-line therapies in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):698-706. View Abstract

  75. Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP® ). Pediatr Blood Cancer. 2017 05; 64(5). View Abstract

  76. Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia. Cold Spring Harb Mol Case Stud. 2016 Jul; 2(4):a000885. View Abstract

  77. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016 08; 63(8):1407-13. View Abstract

  78. Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatr Neurol. 2016 09; 62:66-70. View Abstract

  79. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015 Sep; 90(9):825-30. View Abstract

  80. Thrombopoietin-receptor agonists in children with immune thrombocytopenia. Lancet. 2015 Oct 24; 386(10004):1606-9. View Abstract

  81. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9. View Abstract

  82. Image-guided core needle biopsy in the diagnosis of malignant lymphoma. Eur J Surg Oncol. 2015 Jul; 41(7):852-8. View Abstract

  83. The utility of the DDAVP challenge test in children with low von Willebrand factor. Br J Haematol. 2015 Sep; 170(6):884-6. View Abstract

  84. Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatr Blood Cancer. 2015 02; 62(2):214-218. View Abstract

  85. The use of erythropoietin-stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience. Eur J Haematol. 2014 Aug; 93(2):161-4. View Abstract

  86. Standardized clinical assessment and management plans (SCAMPs): perspectives on a new method to understand treatment decisions and outcomes in immune thrombocytopenia. Semin Hematol. 2013 Jan; 50 Suppl 1:S31-8. View Abstract

  87. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood. 2012 Apr 05; 119(14):3263-8. View Abstract

  88. Trends in anti-D immune globulin for childhood immune thrombocytopenia: usage, response rates, and adverse effects. Am J Hematol. 2012 Mar; 87(3):315-7. View Abstract

  89. Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatr Blood Cancer. 2012 Feb; 58(2):216-20. View Abstract

  90. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer. 2012 Feb; 58(2):221-5. View Abstract

  91. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9. View Abstract

  92. Unsuspected pulmonary emboli in pediatric oncology patients: detection with MDCT. AJR Am J Roentgenol. 2010 May; 194(5):1216-22. View Abstract

  93. Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Ann Hematol. 2010 Jul; 89 Suppl 1:S95-103. View Abstract

  94. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. Am J Hematol. 2010 Feb; 85(2):135-7. View Abstract

  95. Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. Pediatr Blood Cancer. 2009 Jul; 52(7):865-7. View Abstract

  96. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia. 2006 May; 12(3):218-22. View Abstract

  97. Cardiac presentation of ALK positive anaplastic large cell lymphoma. Eur J Haematol. 2005 Dec; 75(6):511-4. View Abstract

  98. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health. 2002 Aug; 38(4):401-4. View Abstract

  99. Transmembrane versus soluble stem cell factor expression in human testis. J Androl. 2000 Jul-Aug; 21(4):579-85. View Abstract

  100. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997 Dec; 99(4):939-44. View Abstract

  101. Ligand linked assembly of Scapharca dimeric hemoglobin. J Biol Chem. 1997 Feb 28; 272(9):5689-94. View Abstract

Education

Medical School

Calcutta College

Kolkata, India

Internship

Calcutta Medical College

Kolkata, India

Residency

Pediatrics and Neurology

Postgraduate Institute of Medical Education and Research

Chandigarh, India

Fellowship

Neurology

Postgraduate Institute of Medical Education and Research

2006, Chandigarh, India

Residency

Pediatric Neurology

Cleveland Clinic

Cleveland, OH

Fellowship

Pediatric Neurology

Cleveland Clinic

Cleveland, OH

Fellowship

Neuromuscular

Mayo Clinic

Rochester, MN

Fellowship

Clinical Neurophysiology (EMG)

Mayo Clinic

Rochester, MN

Publications

Education

Medical School

The Hebrew University

2007, Jerusalem, Israel

Residency

Rabin Medical Center

2013, Petah Tikva, Israel

Fellowship

Microsurgery & Breast Reconstruction

Beth Israel Deaconess Medical Center/Harvard Medical School

2014, Boston, MA

Fellowship

Craniofacial & Pediatric Plastic Surgery

Boston Children's Hospital/Harvard Medical School

2015, Boston, MA

Education

Medical School

University of Connecticut School of Medicine

Farmington, CT

Residency

University of Rochester

Rochester, NY

Fellowship

General Pediatrics

Boston Medical Center

Boston, MA

Education

Undergraduate School

University of Michigan

1991, Ann Arbor, MI

Medical School

University of California, David Geffen School of Medicine

1995, Los Angeles, CA

Residency

Cedars Sinai Medical Center

1999, Los Angeles, CA

Fellowship

Mattel Children’s Hospital at UCLA

2003, Los Angeles, CA

Graduate School

University of California Los Angeles School of Public Health

2005, Los Angeles, CA

Publications
Subscribe to English

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

For questions regarding an appointment, doctor notes, or specific questions related to symptoms/diagnosis, please call the department of clinic directly.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services